| Literature DB >> 32707077 |
Nemanja Despot Marjanovic1, Matan Hofree2, Jason E Chan3, David Canner4, Katherine Wu5, Marianna Trakala4, Griffin G Hartmann5, Olivia C Smith6, Jonathan Y Kim6, Kelly Victoria Evans7, Anna Hudson5, Orr Ashenberg2, Caroline B M Porter2, Alborz Bejnood2, Ayshwarya Subramanian2, Kenneth Pitter8, Yan Yan5, Toni Delorey2, Devan R Phillips2, Nisargbhai Shah9, Ojasvi Chaudhary10, Alexander Tsankov11, Travis Hollmann12, Natasha Rekhtman12, Pierre P Massion13, John T Poirier14, Linas Mazutis10, Ruifang Li15, Joo-Hyeon Lee7, Angelika Amon16, Charles M Rudin17, Tyler Jacks18, Aviv Regev19, Tuomas Tammela20.
Abstract
Tumor evolution from a single cell into a malignant, heterogeneous tissue remains poorly understood. Here, we profile single-cell transcriptomes of genetically engineered mouse lung tumors at seven stages, from pre-neoplastic hyperplasia to adenocarcinoma. The diversity of transcriptional states increases over time and is reproducible across tumors and mice. Cancer cells progressively adopt alternate lineage identities, computationally predicted to be mediated through a common transitional, high-plasticity cell state (HPCS). Accordingly, HPCS cells prospectively isolated from mouse tumors and human patient-derived xenografts display high capacity for differentiation and proliferation. The HPCS program is associated with poor survival across human cancers and demonstrates chemoresistance in mice. Our study reveals a central principle underpinning intra-tumoral heterogeneity and motivates therapeutic targeting of the HPCS.Entities:
Keywords: cell state transition; chromatin state; differentiation; drug resistance; lung cancer; plasticity; single-cell transcriptomics; tumor evolution; tumor heterogeneity; tumor progression
Mesh:
Year: 2020 PMID: 32707077 PMCID: PMC7745838 DOI: 10.1016/j.ccell.2020.06.012
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743